Literature DB >> 29921991

Sickle Cell Hemoglobin C Disease Patient Undergoing Coronary Artery Bypass Grafting with Complete Exchange Blood Transfusion during Cardiopulmonary Bypass.

Francesca Mullins1, Shawn Ott1, Nakia Mister1, Jeffrey Travis1.   

Abstract

Sickle cell disorders are associated with increased risk of sickling and vaso-occlusive complications when undergoing cardiopulmonary bypass (CPB) surgery. Monitoring of certain parameters such as venous and arterial oxygen content, hematocrit, acid base homeostasis, and body temperature are required for a superior outcome. Furthermore, perioperative exchange transfusion has a positive effect on the outcome of surgery and on the survival of patients undergoing heart surgery. Avoiding intraoperative hypoxia and hypothermia, and minimizing hemoglobin S (HbS) and hemoglobin C (HbC) levels with exchange transfusion make bypass surgery relatively safe with enhanced outcomes in these cases. The exact HbS level for conducting cardiac surgery with CPB is not known, however, a HbS level <30% is considered safe for conducting CPB. By using a "discard" cardiotomy reservoir and priming the oxygenator reservoir with donor blood, we were able to reduce the intraoperative circulating HbS and HbC levels to less than 15% and sequester the plasma and clotting factors from the discarded blood using intraoperative plasmapheresis.

Entities:  

Keywords:  Hemoglobin SC disease; cardiopulmonary bypass; exchange transfusion; sickle cell anemia

Mesh:

Year:  2018        PMID: 29921991      PMCID: PMC6002650     

Source DB:  PubMed          Journal:  J Extra Corpor Technol        ISSN: 0022-1058


  5 in total

1.  Sickle cell disease and aortic valve replacement: use of cardiopulmonary bypass, partial exchange transfusion, platelet sequestration, and continuous hemofiltration.

Authors:  S W Sutton; E K Hunley; M A Duncan; R Rodriguez; T P Meyers
Journal:  Tex Heart Inst J       Date:  1999

2.  Current therapy of sickle cell disease.

Authors:  Zakari Y Aliyu; Ashaunta R Tumblin; Gregory J Kato
Journal:  Haematologica       Date:  2006-01       Impact factor: 9.941

3.  Cardiopulmonary bypass without preoperative exchange transfusion in sicklers.

Authors:  Madan M Maddali; Muthukkumar C Rajakumar; Jutta Fahr; Maher J Albahrani; Mohamed A Amna
Journal:  Asian Cardiovasc Thorac Ann       Date:  2006-02

4.  Exchange transfusion before cardiopulmonary bypass in sickle cell disease.

Authors:  Karl A Bocchieri; S Jacob Scheinerman; L Michael Graver
Journal:  Ann Thorac Surg       Date:  2010-07       Impact factor: 4.330

5.  Mitral valve replacement in a patient with sickle cell disease using perioperative exchange transfusion.

Authors:  David Chabot; Robin Sutton
Journal:  J Extra Corpor Technol       Date:  2008-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.